Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2012 | 10:28pm CEST

CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
04/30 CVS HEALTH : Marsh closing pharmacies, including 2 in Anderson
04/28 CVS HEALTH CORP (NYSE : CVS) Releases Report On Prescription Drug Abuse
04/27 CVS HEALTH : To Hold First Quarter 2017 Conference Call
04/27 CVS HEALTH : Report Examines Public Perceptions of Opioid Epidemic, Drug Disposa..
04/26DJExpress Scripts Faces Tough Test -- WSJ
04/24 CVS : Improving Health Care Delivery and Fostering Innovation
04/22 Cherokee Nation sues opioid providers Cherokee Nation sues opioid wholesaler..
04/21 CVS HEALTH CORPORATION : To Hold First Quarter 2017 Conference Call
04/21 CVS HEALTH : expands better-for-you food lineup
04/20 Cherokee Nation sues opioid wholesalers, retailers for abuse
More news
Sector news : Drug Retailers - NEC
04/26 PayPal's profit, revenue beat on higher processing volumes
04/26DJANTHEM : Says ACA Payment Loss Could Cause 20% Premium Hike -- Update
04/26DJExpress Scripts Faces Tough Test -- WSJ
04/25DJEXPRESS SCRIPTS : Faces a Future Without Its Biggest Customer
04/24DJEXPRESS SCRIPTS : Says It Will Lose Anthem, Its Biggest Customer, in 2020
More sector news : Drug Retailers - NEC
News from SeekingAlpha
04/28 Tematica's Take On Trump's Tax Proposal
04/27 My Dividend Growth Portfolio - Q1 2017 Summary
04/26 The Best Of The Blue Chips (And The Worst)
04/25 Sixth Portfolio Review - 'The Accelerated Dividend Portfolio'
04/25 McKesson Remains Undervalued
Advertisement
Financials ($)
Sales 2017 184 255 M
EBIT 2017 10 131 M
Net income 2017 5 470 M
Debt 2017 24 914 M
Yield 2017 2,35%
P/E ratio 2017 15,51
P/E ratio 2018 13,88
EV / Sales 2017 0,60x
EV / Sales 2018 0,57x
Capitalization 85 391 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 86,3 $
Spread / Average Target 4,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP4.47%85 391
WALGREENS BOOTS ALLIAN..4.57%93 545
EXPRESS SCRIPTS HOLDIN..-10.83%36 407
MCKESSON CORPORATION-1.54%29 325
CARDINAL HEALTH INC0.86%22 899
AMERISOURCEBERGEN CORP..4.94%17 828
More Results